A global pharmaceutical company specializing in vaccines wanted to prove the economic value of their newly developed COVID-19 vaccine. They needed a cost-effectiveness model comparing their vaccine to those currently in use, along with an economic systematic literature review (SLR) to support the model and provide information to discover a niche for their product.
The rapidly changing landscape of COVID-19 posed several challenges. By the time the economic SLR was finished, the information had already become outdated. Most of the articles considered initial COVID-19 vaccinations, while booster vaccinations were more relevant. In addition, new variants of COVID-19 were not researched in the identified articles.